Jorge A. Florindez

Jorge A. Florindez

Auto-generated profile, based on publicly available information

Jorge A. Florindez

Division of Medical Oncology Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
ARAndres Ramirez‐Gamero
Andres Ramirez‐Gamero
HMHumberto Martinez-Cordero
Humberto Martinez-Cordero
BBBrady E. Beltrán
Brady E. Beltrán
JFJorge Florindez
Jorge Florindez
LMLuis Malpica
Luis Malpica
JCJorge J Castillo
Jorge J Castillo

10 August 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JFJorge A. Florindez
Jorge A. Florindez
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
IRIsildinha M. Reis
Isildinha M. Reis
ILIzidore S Lossos
Izidore S Lossos

7 August 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
JFJorge A. Florindez
Jorge A. Florindez
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
IRIsildinha M. Reis
Isildinha M. Reis
ILIzidore S Lossos
Izidore S Lossos

1 February 2015 in Clinical Nephrology
Verified
Journal Article
Closed access
KLKarlo Lizarraga
Karlo Lizarraga
JFJorge A. Florindez
Jorge A. Florindez
PDPirouz Daftarian
Pirouz Daftarian
DADavid Andrews
David Andrews
LOLuís Ortega-Medina
Luís Ortega-Medina
ANAli Nayer
Ali Nayer
Anti-glomerular basement membrane (GBM) disease is a severe inflammatory renal disorder due to pathogenic autoantibodies directed mainly against the α3 chain of type IV collagen. In ~1/4 of patients with anti-GBM disease, antineutrophil cytoplasmic antibodies (ANCA) predominantly with myeloperoxidase (MPO) specificity can be detected. Although the inciting stimuli leading to the development of an immune response against the type IV collagen and neutrophils are unknown, evidence indicates that both genetic and environmental factors play a role. Of note, molecular mimicry between self-antigens and nonself-antigens such as antigenic determinants of microorganisms has been implicated in the pathogenesis of anti-GBM disease and ANCA-associated vasculitis. A mosquito-borne viral illness highly prevalent in the tropics and subtropics, dengue can be complicated by acute renal failure, proteinuria, hematuria and glomerulonephritis. We present a 66-year-old woman who was diagnosed with dengue infection and rapidly progressive glomerulonephritis during an outbreak of dengue in Honduras in the summer of 2013. Renal biopsy revealed severe crescentic glomerulonephritis. Immunofluorescence examination demonstrated strong linear IgG deposition along glomerular capillary walls. Serologic tests demonstrated antibodies against GBM, MPO and platelet glycoproteins. The patient was diagnosed with anti-GBM disease associated with p-ANCA with MPO specificity. Despite heavy immunosuppression and plasmapheresis, IgG titers against dengue virus continued to rise confirming the diagnosis of acute dengue infection. We present the first reported case of anti-GBM disease associated with p-ANCA with MPO specificity during dengue infection. This report calls for a heightened awareness of autoimmunity leading to crescentic glomerulonephritis in patients with dengue infection.

21 October 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SISunil Girish Iyer
Sunil Girish Iyer
RKRuss Kuker
Russ Kuker
JFJorge A. Florindez
Jorge A. Florindez
ESEduardo Edelman Saul
Eduardo Edelman Saul
ATAsaad Trabolsi
Asaad Trabolsi
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio
Breast extranodal marginal zone lymphoma (EMZL) is a rare malignancy. We performed the largest published to date single-center retrospective analysis of 13 patients with breast EMZL focusing on clinical characteristics and treatment-related outcomes. The rarity of this disease at our center was concordant with the prevalence reported in the literature, with breast EMZL comprising 2% of 654 MZL cases. Most patients presented with stage I-II disease however four (30.8%) patients had stage IV disease mostly due to occult bone marrow (BM) involvement. Interestingly, EMZL was frequently non-FDG avid (66.7%) on staging PET/CT. With a median follow-up of 3.1 years (range 5 months to 10.2 years), the 3-year progression free survival was 68.7% (95%CI 30.2%–88.9%) and overall survival 80.2% (95%CI 40.3%-94.8%). No patient experienced higher-grade transformation. Herein we show that localized breast EMZL can be effectively treated with radiation therapy providing long term disease control.

22 August 2022 in Hematological Oncology
Verified
Journal Article
Closed access
JFJorge A. Florindez
Jorge A. Florindez
ILIzidore S. Lossos
Izidore S. Lossos
JAJuan Pablo Alderuccio
Juan Pablo Alderuccio